Eugia – Recall of methocarbamol injection

- On March 28, 2024, Eugia announced a consumer-level recall of one lot of methocarbamol injection because of a customer complaint for the presence of white particles floating inside the vial.

- This recalled lot was distributed nationwide from January 12, 2024 and January 16, 2024.

<table>
<thead>
<tr>
<th>Product Description</th>
<th>NDC number</th>
<th>Lot number (Exp Date)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methocarbamol injection, 1000 mg/10 mL (100 mg/mL), single dose vial</td>
<td>55150-223-10</td>
<td>3MC23011 (11/2026)</td>
</tr>
</tbody>
</table>

- Methocarbamol injection is used as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.

- Administration of an injectable product that contains particulate matter may result in local irritation or swelling. If the particulate matter reaches the blood vessels or is injected intravascularly it can travel to various organs and block blood vessels in the heart, lungs or brain which can cause stroke and even lead to death.

- To date, Eugia has not received any reports of adverse events related to this recall.

- Anyone with the affected product on hand should discontinue use, stop distribution and quarantine product immediately. Patients should contact their healthcare provider if they have experienced any problems that may be related to using the recalled product.

- Consumers may contact Eugia by phone at 1-866-850-2876 or by email at pvg@aurobindousa.com for more information.